Piramal Pharma Ropes In Mrunal Thakur As Its Brand Ambassador For Lacto Calamine®

* Launches a brand new new multi-media campaign – ‘Oily skin hai to Lacto Calamine’

Piramal Pharma Limited’s India Consumer Healthcare (ICH) today announced its association with popular actress, Mrunal Thakur as its new brand ambassador for its flagship skincare brand, Lacto Calamine®. With a legacy of offering effective skincare solutions, Lacto Calamine® aims to maintain its position as a leading expert for skincare.

Lacto Calamine® has long been a trusted name in skincare, recognized for its expertise and versatile benefits. Valued for its gentle yet effective formula, it is widely used and recommended by consumers to address a variety of skincare concerns, from oily skin and acne to patchy skin, rashes, and blemishes. The key ingredients—Kaolin Clay, which absorbs excess oil; Zinc Oxide, which unclogs pores and helps prevent pimples; and Glycerin, which retains moisture—work together to promote healthy, clear skin. Over the last few decades, the brand has expanded its reach across multiple channels, including pharmacies, cosmetics and general stores, hyper and super markets, other modern retail outlets, and e-commerce platforms.

The brand intends to strengthen its position in the skincare market by becoming the preferred brand for consumers facing problems related to oily skin. Building on this positioning, Lacto Calamine® is launching its new multi-media campaign – ‘Oily skin hai to Lacto Calamine’ with Mrunal Thakur for its range of products. In the next 18-24 months, the brand plans to expand its presence with a wider range of products and in newer channels and stores and accelerate growth on ecommerce portals.

Nandini Piramal, Chairperson, Piramal Pharma said, "The Indian skincare industry is growing rapidly, driven by rising consumer awareness and demand for personalized products. To meet these evolving needs, Lacto Calamine has expanded from its iconic lotion to a full skincare range with over 20 new products. With Mrunal Thakur as our new brand ambassador, we're reinforcing our commitment to build a credible and relevant brand. Her association, combined with our expanded range of sunscreens and face washes, will help us connect with a wider audience and strengthen our position as a trusted skincare brand. Known for her versatility and radiant presence, Mrunal will play a key role in introducing our new products and increasing the brand's visibility across diverse consumer groups.”

Speaking on this association with Lacto Calamine®, Mrunal Thakur said, "I am honored to partner with a brand that has earned the trust of generations for its reliable skincare solutions. Lacto Calamine's blend of innovation and authenticity truly reflects my own values when it comes to beauty. I’m excited to introduce these thoughtfully crafted products to a wider audience and inspire confidence in women by promoting healthy, radiant skin."

About Piramal Consumer Healthcare:

Piramal Pharma’s Consumer Healthcare portfolio comprises 25+ brands with offerings spanning across multiple categories. It aims to be among the top three over the-counter (OTC) product companies in India. Over the last two years, the business has invested significantly in various growth levers. The Company’s strategy of expanding the product portfolio and distribution network has worked well and the Consumer Healthcare business is evolving into a strong player in India’s OTC market. For more information visit:  Piramal Pharma Consumer Healthcare

About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.